MarketBeat provided stock average ratings while Leerink Partners upgraded and Barclays raised its price objective for Summit Therapeutics.
1 report, 1 independent
Updated Wed 00:00
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MarketBeat provided stock average ratings while Leerink Partners upgraded and Barclays raised its price objective for Summit Therapeutics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Summit Therapeutics
biopharmaceutical company
-
MarketBeat
American personal finance blog
-
Leerink partners
U.S. investment bank
-
Barclays
British bank
Related events
- MarketBeat reported an average stock rating for Superior Group of Companies.
- MarketBeat provided consensus ratings for MACOM as Susquehanna dropped its price objective and Needham & Company increased its target and gave a buy rating.
- MarketBeat reported average rating data as Barclays raised its price target and TD Cowen raised its price target for Brinker International.
- MarketBeat provided average rating data for the stock, and Citigroup began coverage on Whitehawk Therapeutics shares.
- MarketBeat provided stock ratings for Paylocity Holding Corporation, alongside SEC filings and price target updates from Cantor Fitzgerald and Citizens Jmp.